A Turning Point in Women’s Health
For over two decades, women have been warned about the risks of hormone therapy for menopause. Labels featured the most severe warning possible — a “black box” — suggesting that estrogen therapy could increase the risk of breast cancer, heart disease, and dementia.
But now, the FDA has announced the removal of that black box warning from many estrogen-related menopausal hormone therapy (MHT) products, marking a major shift in women’s healthcare. This decision reflects years of evolving science showing that hormone therapy can be safe and effective — especially when started at the right time, in the right women, and with the right formulations.
Why the Change Happened
The original warning was based on early 2000s findings from the Women’s Health Initiative (WHI). At the time, data suggested an increased risk of heart disease and breast cancer among hormone users. However, later studies showed that those risks were largely dependent on age and timing — women who started therapy within 10 years of menopause or before age 60 saw significantly more benefits and fewer risks.
Newer research has also clarified that:
- Local vaginal estrogen (used for dryness or discomfort) has minimal systemic absorption and does not carry the same risks.
- Lower doses and transdermal forms (patches, gels) may be safer for some women.
- Hormone therapy can help protect bone health, improve sleep, restore sexual health, and relieve severe hot flashes and night sweats.
Recognizing this, the FDA decided it was time to remove outdated, overly broad warnings that discouraged women from seeking treatment.
What the FDA’s Decision Means
The FDA’s new policy will:
- Remove the “black box” warning for cardiovascular disease, breast cancer, and dementia on many MHT products.
- Keep important cautions where appropriate — for example, estrogen-only therapy without progesterone still carries a warning about endometrial cancer risk in women with a uterus.
- Emphasize personalized care, allowing providers to tailor therapy based on age, health history, and symptom severity.
This change encourages a more balanced, evidence-based approach — giving women and their doctors the freedom to make decisions based on individual risk, not outdated fear.
What This Means for You
If you’ve been suffering through menopause symptoms — such as hot flashes, brain fog, fatigue, vaginal dryness, or low libido — but avoided hormone therapy because of past warnings, it may be time to revisit your options.
At Prestige Medical Group, we believe every woman deserves personalized care through menopause and beyond. With updated FDA guidance, providers can now confidently discuss safe, customized options that fit your goals and health profile.
Our Approach at Prestige Medical Group
We create individualized treatment plans to restore balance and vitality, which may include:
- BioTE® bioidentical hormone therapy
- Peptide and regenerative therapies (such as NAD+ and Glow Blend)
- Sexual health treatments like MonaLisa Touch® and Clitoxin
Each plan is customized to help women feel like themselves again — vibrant, confident, and empowered.
Your Next Step
If you’re experiencing menopause symptoms or want to explore whether hormone therapy is right for you, our team is here to help.
📞 Call (949) 825-7650 or visit here to schedule your consultation today.
Let’s move past fear and toward a new era of women’s health — one where hormones are discussed openly, options are clear, and wellness is within reach.